Precision Biosciences (DTIL) Return on Capital Employed (2019 - 2026)
Precision Biosciences' (DTIL) quarterly Return on Capital Employed came in at 27.66% in Q1 2026, up 970.0% year-on-year from 2.59% in Q1 2025, and up 38.98% on a QoQ basis from 45.33% in Q4 2025.
Precision Biosciences (DTIL) Return on Capital Employed (2019 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 8 years of Return on Capital Employed data on file, last reported at 27.66% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 970.0% year-over-year to 27.66% in Q1 2026; TTM through Mar 2026 was 27.66%, a 970.0% increase from a year earlier, with the FY2025 full-year figure at 38.21%, down 1855.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 27.66%, up from 45.33% in the prior quarter.
- Over the last five years, Return on Capital Employed for DTIL reached as high as 5.13% in Q2 2024 and fell as low as 103.8% in Q3 2025.
- Historically, Return on Capital Employed has averaged 39.86% across 5 years, with a median of 37.36% in 2025.
- Across the five-year window, Return on Capital Employed jumped 4229 bps in 2022 and plunged 9282 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 42.85% in 2022, then rose by 9 bps to 39.02% in 2023, then surged by 48 bps to 20.15% in 2024, then sank by 125 bps to 45.33% in 2025, then jumped by 39 bps to 27.66% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 27.66% in Q1 2026, 45.33% in Q4 2025, and 103.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Precision Biosciences | 178.85 Mn | 150.56 Mn | - | -27.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.66% |
| Dec 31, 2025 | -45.33% |
| Sep 30, 2025 | -103.80% |
| Jun 30, 2025 | -87.40% |
| Mar 31, 2025 | -37.36% |
| Dec 31, 2024 | -20.15% |
| Sep 30, 2024 | -10.98% |
| Jun 30, 2024 | -5.13% |
| Mar 31, 2024 | -24.88% |
| Dec 31, 2023 | -39.02% |
| Sep 30, 2023 | -33.46% |
| Jun 30, 2023 | -31.65% |
| Mar 31, 2023 | -39.94% |
| Dec 31, 2022 | -42.85% |
| Sep 30, 2022 | -45.81% |
| Jun 30, 2022 | -53.50% |
| Mar 31, 2022 | -28.67% |
| Dec 31, 2021 | -21.47% |
| Sep 30, 2021 | -16.72% |
| Jun 30, 2021 | -22.21% |